JP2006515607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515607A5 JP2006515607A5 JP2006500313A JP2006500313A JP2006515607A5 JP 2006515607 A5 JP2006515607 A5 JP 2006515607A5 JP 2006500313 A JP2006500313 A JP 2006500313A JP 2006500313 A JP2006500313 A JP 2006500313A JP 2006515607 A5 JP2006515607 A5 JP 2006515607A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antimuscarinic agent
- pharmaceutically effective
- effective dose
- interval
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003149 muscarinic antagonist Substances 0.000 claims 12
- 239000002775 capsule Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960004045 tolterodine Drugs 0.000 claims 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical group C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002677 darifenacin Drugs 0.000 claims 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229960005434 oxybutynin Drugs 0.000 claims 1
- 229960003855 solifenacin Drugs 0.000 claims 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44169003P | 2003-01-22 | 2003-01-22 | |
| PCT/IB2004/000169 WO2004064821A1 (en) | 2003-01-22 | 2004-01-14 | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515607A JP2006515607A (ja) | 2006-06-01 |
| JP2006515607A5 true JP2006515607A5 (https=) | 2006-12-28 |
Family
ID=32771960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500313A Pending JP2006515607A (ja) | 2003-01-22 | 2004-01-14 | 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20060047007A1 (https=) |
| EP (1) | EP1589958B2 (https=) |
| JP (1) | JP2006515607A (https=) |
| KR (1) | KR20050096147A (https=) |
| CN (1) | CN1741796A (https=) |
| AT (1) | ATE432070T1 (https=) |
| AU (1) | AU2004206110A1 (https=) |
| BR (1) | BRPI0406861A (https=) |
| CA (1) | CA2514022C (https=) |
| DE (1) | DE602004021233D1 (https=) |
| ES (1) | ES2324712T5 (https=) |
| IL (1) | IL169362A0 (https=) |
| MX (1) | MXPA05007767A (https=) |
| PL (1) | PL377995A1 (https=) |
| TW (1) | TW200418447A (https=) |
| WO (1) | WO2004064821A1 (https=) |
| ZA (1) | ZA200505026B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DK2210605T3 (en) * | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
| ES2322148T3 (es) * | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| PT1986642E (pt) * | 2006-02-13 | 2014-01-30 | Orient Pharma Samoa Co Ltd | Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia |
| WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| WO2011109403A1 (en) * | 2010-03-01 | 2011-09-09 | Xenoport, Inc. | Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| SK287111B6 (sk) * | 1998-08-27 | 2009-12-07 | Pharmacia & Upjohn Ab | Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| NZ518309A (en) * | 1999-11-11 | 2003-05-30 | Pharmacia Ab | Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours |
-
2004
- 2004-01-14 MX MXPA05007767A patent/MXPA05007767A/es unknown
- 2004-01-14 DE DE602004021233T patent/DE602004021233D1/de not_active Expired - Lifetime
- 2004-01-14 CN CNA2004800025658A patent/CN1741796A/zh active Pending
- 2004-01-14 WO PCT/IB2004/000169 patent/WO2004064821A1/en not_active Ceased
- 2004-01-14 BR BR0406861-0A patent/BRPI0406861A/pt not_active IP Right Cessation
- 2004-01-14 KR KR1020057013495A patent/KR20050096147A/ko not_active Ceased
- 2004-01-14 AT AT04702017T patent/ATE432070T1/de not_active IP Right Cessation
- 2004-01-14 ES ES04702017T patent/ES2324712T5/es not_active Expired - Lifetime
- 2004-01-14 PL PL377995A patent/PL377995A1/pl not_active Application Discontinuation
- 2004-01-14 AU AU2004206110A patent/AU2004206110A1/en not_active Abandoned
- 2004-01-14 JP JP2006500313A patent/JP2006515607A/ja active Pending
- 2004-01-14 EP EP04702017A patent/EP1589958B2/en not_active Expired - Lifetime
- 2004-01-14 CA CA2514022A patent/CA2514022C/en not_active Expired - Fee Related
- 2004-01-20 TW TW093101626A patent/TW200418447A/zh unknown
- 2004-01-22 US US10/762,726 patent/US20060047007A1/en not_active Abandoned
-
2005
- 2005-06-21 ZA ZA200505026A patent/ZA200505026B/xx unknown
- 2005-06-23 IL IL169362A patent/IL169362A0/en unknown
-
2007
- 2007-02-21 US US11/677,071 patent/US20070155838A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| ES2358763T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid. | |
| JP2009525343A5 (https=) | ||
| ES2525648T3 (es) | Formulaciones galénicas que comprenden Aliskiren | |
| JP2005512995A5 (https=) | ||
| CA2829101C (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2014532638A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| JP2012502037A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| WO2009104932A3 (ko) | 복합제제 | |
| JP2014516942A5 (https=) | ||
| JP2005537268A5 (https=) | ||
| JP2012505884A5 (https=) | ||
| JPWO2021099783A5 (https=) | ||
| JP2012521355A5 (https=) | ||
| JP2012167125A5 (https=) | ||
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2020523334A5 (https=) | ||
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| JP2006515607A5 (https=) | ||
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| JP2006517557A5 (https=) |